SOURCE-LINKED STUDY SUMMARY
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.
Abstract summarizedQuality not appraised
- What was studied
- Randomized comparison of semaglutide with placebo for long-term weight management, with behavioral intervention in both groups.
- Who / model studied
- 304 adults with obesity, or overweight with a weight-related condition, without diabetes; studied for 104 weeks. Most participants were women and White.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Both primary outcomes favored semaglutide: average weight fell 15.2% versus 2.6%, and 77.1% versus 34.4% lost at least 5%. Digestive adverse events occurred in 82.2% versus 53.9%, mostly mild or moderate.
- Limitations & context
- Study limitations were not stated in the abstract. Methodological quality has not been appraised.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1038/s41591-022-02026-4